Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleINFLAMMATION, IMMUNOPHARMACOLOGY, AND ASTHMA

Pharmacological Characterization of Sch527123, a Potent Allosteric CXCR1/CXCR2 Antagonist

Waldemar Gonsiorek, Xuedong Fan, David Hesk, James Fossetta, Hongchen Qiu, James Jakway, Motasim Billah, Michael Dwyer, Jianhua Chao, Gregory Deno, Art Taveras, Daniel J. Lundell and R. William Hipkin
Journal of Pharmacology and Experimental Therapeutics August 2007, 322 (2) 477-485; DOI: https://doi.org/10.1124/jpet.106.118927
Waldemar Gonsiorek
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xuedong Fan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Hesk
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James Fossetta
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hongchen Qiu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James Jakway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Motasim Billah
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Dwyer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jianhua Chao
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gregory Deno
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Art Taveras
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel J. Lundell
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. William Hipkin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

In neutrophils, growth-related protein-α (CXCL1) and interleukin-8 (CXCL8), are potent chemoattractants (Cytokine14:27–36, 2001; Biochemistry42:2874–2886, 2003) and can stimulate myeloperoxidase release via activation of the G protein-coupled receptors CXCR1 and CXCR2. The role of CXCR1 and CXCR2 in the pathogenesis of inflammatory responses has encouraged the development of small molecule antagonists for these receptors. The data presented herein describe the pharmacology of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5-methyl-furan-2-yl)-propyl]amino]-3,4-dioxo-cyclobut-1-enylamino}-benzamide (Sch527123), a novel antagonist of both CXCR1 and CXCR2. Sch527123 inhibited chemokine binding to (and activation of) these receptors in an insurmountable manner and, as such, is categorized as an allosteric antagonist. Sch527123 inhibited neutrophil chemotaxis and myeloperoxidase release in response to CXCL1 and CXCL8 but had no effect on the response of these cells to C5a or formyl-methionyl-leucyl-phenylalanine. The pharmacological specificity of Sch527123 was confirmed by testing in a diversity profile against a panel of enzymes, channels, and receptors. To measure compound affinity, we characterized [3H]Sch527123 in both equilibrium and nonequilibrium binding analyses. Sch527123 binding to CXCR1 and CXCR2 was both saturable and reversible. Although Sch527123 bound to CXCR1 with good affinity (Kd = 3.9 ± 0.3 nM), the compound is CXCR2-selective (Kd = 0.049 ± 0.004 nM). Taken together, our data show that Sch527123 represents a novel, potent, and specific CXCR2 antagonist with potential therapeutic utility in a variety of inflammatory conditions.

Footnotes

  • Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.

  • doi:10.1124/jpet.106.118927.

  • ABBREVIATIONS: IL-8, interleukin-8 (CXCL8); CXCL5, endothelial-cell derived neutrophil activating protein 78; fMLP, formyl-methionyl-leucyl-phenylalanine; CXCL6, granulocyte chemotactic protein-2; CXCL1-3, growth-related protein-α,-β, and -γ;[35S]GTPγS, guanosine 5′-[γ-35S]-triphosphate, triethylammonium salt; IL-3, interleukin-3; MPO, myeloperoxidase; CXCL7, neutrophil-activating peptide-2; FBS, fetal bovine serum; RLU, relative light intensity unit; WGA-SPA, wheat germ agglutinin bead-scintillation proximity assay; Sch527123, 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5-methyl-furan-2-yl)-propyl]amino]-3,4-dioxo-cyclobut-1-enylamino}-benzamide; repertaxin, (R)(–)-2-(4-isobutylphenyl)propionyl meth-anesulfonamide; SB-225002, N-(2-hydroxy-4-nitrophenyl)-N′-(2-bromophenyl)urea; SB-332235, N-(2-hydroxy-3-sulfamyl-4-chlorophenyl)-N′-(2,3-dichlorophenyl)urea; SB-468477, N-(2-hydroxy-3-dimethylsulfonylamido-4-chlorophenyl)-N′-(2-bromophenyl)-N″-cyanoguanidine; h, human; PMN, neutrophil(s); HPLC, high-performance liquid chromatography; 873140, 4-{[4-({(3R)-1-butyl-3-[(R)-cyclohexyl(hydroxy)methyl]-2,5-dioxo-1,4,9-triazaspiro[5,5]undec-9-yl}methyl)phenyl]oxy}benzoic acid hydrochloride; CCL5, regulated on activation normal T cell expressed and secreted; TAK-220, 1-acetyl-N-{3-[4-(4-carbamoylbenzyl)piperidin-1-yl]propyl}-N-(3-chloro-4-methylphenyl)piperidine-4-carboxamide.

    • Received December 21, 2006.
    • Accepted May 7, 2007.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 385 (3)
Journal of Pharmacology and Experimental Therapeutics
Vol. 385, Issue 3
1 Jun 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Pharmacological Characterization of Sch527123, a Potent Allosteric CXCR1/CXCR2 Antagonist
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleINFLAMMATION, IMMUNOPHARMACOLOGY, AND ASTHMA

Pharmacological Characterization of Sch527123, a Potent Allosteric CXCR1/CXCR2 Antagonist

Waldemar Gonsiorek, Xuedong Fan, David Hesk, James Fossetta, Hongchen Qiu, James Jakway, Motasim Billah, Michael Dwyer, Jianhua Chao, Gregory Deno, Art Taveras, Daniel J. Lundell and R. William Hipkin
Journal of Pharmacology and Experimental Therapeutics August 1, 2007, 322 (2) 477-485; DOI: https://doi.org/10.1124/jpet.106.118927

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleINFLAMMATION, IMMUNOPHARMACOLOGY, AND ASTHMA

Pharmacological Characterization of Sch527123, a Potent Allosteric CXCR1/CXCR2 Antagonist

Waldemar Gonsiorek, Xuedong Fan, David Hesk, James Fossetta, Hongchen Qiu, James Jakway, Motasim Billah, Michael Dwyer, Jianhua Chao, Gregory Deno, Art Taveras, Daniel J. Lundell and R. William Hipkin
Journal of Pharmacology and Experimental Therapeutics August 1, 2007, 322 (2) 477-485; DOI: https://doi.org/10.1124/jpet.106.118927
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Population PK/PD analysis of sutimlimab
  • CCR6 selective antagonist in homeostasis and inflammation
  • PK/PD of Dexamethasone in LPS-Challenged Rats
Show more Inflammation, Immunopharmacology, and Asthma

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics